Enhanced APPAMP Compounds and Delivery Systems for Cancer Treatment

This inventive concept introduces direct improvements and enhancements to the original APPAMP compounds, focusing on novel delivery systems, combination therapies, and improved manufacturing processes to enhance efficacy, safety, and efficiency in cancer treatment.

The original APPAMP compounds, disclosed in the patent application 4-[[(7-aminopyrazolo[1,5-a]pyrimidin-5-yl)amino]methyl]piperidin-3-ol compounds as CDK inhibitors, demonstrated promising anti-cancer properties. However, the existing patent has limitations in terms of delivery, bioavailability, and manufacturing processes. This inventive concept addresses these limitations by introducing controlled-release matrices, biodegradable polymers, combination therapies, and novel crystalline forms to improve the overall treatment outcomes.

The inventive concept comprises five distinct aspects: (1) a system for delivering APPAMP compounds using controlled-release matrices and biodegradable polymers, ensuring a predetermined rate of release; (2) a method for treating cancer by combining APPAMP compounds with chemotherapy agents to enhance efficacy; (3) a pharmaceutical composition incorporating APPAMP compounds and cyclodextrin to improve solubility; (4) a novel crystalline form of APPAMP compounds characterized by specific X-ray diffraction patterns; and (5) an improved process for preparing APPAMP compounds involving enzymatic resolution to enhance yield and purity. These innovations collectively improve the safety, efficacy, and efficiency of APPAMP compounds in cancer treatment.

The new claims introduce novel and non-obvious improvements to the original APPAMP compounds, including the use of controlled-release matrices, combination therapies, and novel crystalline forms. The inventive step lies in the identification of these specific limitations and the development of targeted solutions to address them, resulting in a more effective and efficient treatment approach.

Alternative embodiments of the inventive concept may include variations in the controlled-release matrix composition, different chemotherapy agents for combination therapy, or alternative solubility enhancers. Additionally, the novel crystalline form could be adapted for use in other pharmaceutical applications, and the enzymatic resolution process could be applied to other compound classes.

The enhanced APPAMP compounds and delivery systems have significant commercial potential in the oncology market, with potential applications in various cancer types. The improved manufacturing process and novel crystalline form may also attract interest from pharmaceutical companies seeking to enhance their product portfolios.